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Plant microRNAs as novel 
immunomodulatory agents
Duccio Cavalieri1,2, Lisa Rizzetto1, Noemi Tocci1, Damariz Rivero3, Elisa Asquini1, Azeddine Si-
Ammour1, Elena Bonechi3, Clara Ballerini3 & Roberto Viola1
An increasing body of literature is addressing the immuno-modulating functions of miRNAs which 
include paracrine signaling via exosome-mediated intercellular miRNA. In view of the recent 
evidence of intake and bioavailability of dietary miRNAs in humans and animals we explored the 
immuno-modulating capacity of plant derived miRNAs. Here we show that transfection of synthetic 
miRNAs or native miRNA-enriched fractions obtained from a wide range of plant species and organs 
modifies dendritic cells ability to respond to inflammatory agents by limiting T cell proliferation and 
consequently dampening inflammation. This immuno-modulatory effect appears associated with 
binding of plant miRNA on TLR3 with ensuing impairment of TRIF signaling. Similarly, in vivo, plant 
small RNAs reduce the onset of severity of Experimental Autoimmune Encephalomyelities by limiting 
dendritic cell migration and dampening Th1 and Th17 responses in a Treg-independent manner. 
Our results indicate a potential for therapeutic use of plant miRNAs in the prevention of chronic-
inflammation related diseases.
The discovery of microRNAs (miRNAs) and their interaction with the gene expression machinery in most organisms 
is one of the major scientific breakthroughs in recent years1. The regulatory effects of miRNAs have been mainly eluci-
dated studying their expression within a given cell type2. Endogenous miRNAs are known to mediate gene expression of 
cognate messenger RNAs (mRNAs) in a sequence specific manner by affecting, via the RNA-induced silencing complex 
(RISC), fundamental processes ranging from cell development to cancer to immune regulation3–7. Yet, even still contro-
versial, miRNAs have been shown also to act outside the cell from which they originate by long distance transport8–13.
The inter-cellular mode-of-action of miRNAs has led to suggestions for therapeutic applications14 in analogy 
with exogenously supplemented small interfering RNAs (siRNAs), which induce degradation of sequence-specific 
homologous mRNA via RNA interference. In the case of siRNAs, “off-targeting effects” and adverse reactions 
such as the promotion of inflammation15,16 have so far hampered their wider adoption as therapeutic appli-
cation17. Exogenous double stranded RNA (dsRNA) as well as single stranded RNA (ssRNAs) are intercepted 
by the Pathogen Recognition Receptors (PRRs) of the innate immune system such as membrane-bound 
Toll-Like Receptors (TLRs) and cytoplasmic receptors abundant in the immune cell18,19 and activate an inflam-
matory response through the type I IFN system20. While TLR7 and TLR8 recognize ssRNAs21, TLR3 binds 
to both single stranded22 and double stranded viral RNAs23,24. TLR3 has also been shown to mediate siRNA 
non-sequence-specific immune suppression through the type I IFN system in cultured mammalian cells20. 
TLR7 and TLR8 also appear to be involved in siRNA pro-inflammatory effects25 and in miRNA-mediated para-
crine loop between cancer cells and immune cells present in the tumor microenvironment with TLR-mediated 
pro-metastatic inflammatory response that ultimately may lead to tumor growth and metastasis26.
In addition to intercellular exchange within organisms8,26,27, inter-organismal miRNA exchanges are also known 
to occur including between taxonomic kingdoms as suggested by the recently reported presence of dietary plant 
microRNA in plasma and organs of humans and animals10,28–30. These latter findings raise paradigm-changing 
questions concerning our understanding of diet-health interactions. However, the validity of these claims has been 
challenged as some authors consider artefactual the detection of dietary plant miRNA sequences in the plasma 
after different feeding regimes28,31–33 while others do not question the presence of plant miRNAs in plasma or 
internal organs, but note that the reported copy number of individual sequences appears too low to be biologically 
relevant28,34. Plant-based dietary delivery of miRNA for therapeutic purposes has also been proposed10,35.
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Since the immune function is the likely mediator of such interactions we have sought to explore the impact 
of plant miRNAs on dendritic cells (DCs), a component of the innate immune system present in the gut and 
responsible for instructing T cells to react and adapt to environmental challenges. Here we show that synthetic 
Fragaria vesca miR168 at physiological concentrations reduce inflammation mediated by TLR agonists via a 
TLR3-mediated mechanism. Indeed, this efficacy was not limited to miRNA from strawberry but was extended to 
sRNAs extracts from a wide variety of plant tissues and species. Furthermore, treatment with plant sRNAs could 
systemically reduce inflammation and prevent symptoms of multiple sclerosis in an Experimental Autoimmune 
Encephalomyelities (EAE) mouse model. These results provide a novel mechanistic explanation for known bene-
ficiary effects exerted by fruit and vegetable in the prevention of inflammation associated disorders.
Results
Strawberry fruit FvmiR168 affects DC properties and their ability to respond to inflamma-
tory stimuli by limiting T cell proliferation. For initial experiments we tested the immuno-modula-
tory efficacy of Fragaria vesca 3′ end methylated miR168 (Table 1), one of the most abundant miRNAs present 
in strawberry fruits, an example of edible miRNA rich plant tissue that is consumed unprocessed. When 
human monocyte-derived DCs were treated with FvmiR168 complexed with DOTAP at miRNA concentra-
tions up to 10 μ g/ml,no effect was observed (Supplementary Fig. 1). However, when Fvmir168 pre-treated 
DCs were challenged with the inflammatory agents LPS or polyI:C, a significant reduction of their inflam-
matory response was observed (Fig. 1). FvmiR168 decreased LPS- and PolyI:C-induced production of IL-1β 
and TNFα (Fig. 1a, Student t-test, p < 0.05). Fvmir168 also reduced the levels of CD80, CD86, CD83 and the 
class II immuno-histocompatibility complex (HLA-DR) (Fig. 1b, p < 0.05). Significantly, these effects were 
observed at a concentration of 10 ng/mL, a level three order of magnitude lower than that required to induce 
a similar effect by human anti-inflammatory miRNAs36,37. FvmiR168 treated-DCs also showed a reduced abil-
ity to induce T cell proliferation in the presence of LPS or polyI:C (Fig. 1c, p < 0.01). The amount of IFNγ 
produced by T cell was also reduced (p < 0.01), in accordance with the reduced ability of DCs to secrete 
IL-12p70 (Fig. 1d, p < 0.01). Th1 cell differentiation was indeed impaired by the FvmiR168 pre-treatment of 
DCs as revealed by reduction of both Tbet and IFNγ expression (p < 0.01). On the other hand, as expected, 
Th2 differentiation was not affected (Fig. 1e). FvmiR168 treated-DCs also showed a significant reduction in 
the expression of CCR7 (Fig. 1f, p < 0.01), a molecule known to guide DCs to and within lymphoid organs38, 
suggesting a defect in their migration ability.
FvmiR168 interacts with DCs through TLR3. Extensive binding of FvmiR168 to DCs was observed 
when these cells were exposed to fluorescein-labeled FvmiR168 and analysed by flow cytometry (Fig. 2a) and 
fluorescence microscopy (Fig. 2b). FvmiR168 binding to DCs was reduced by pre-treatment with specific anti-
bodies against TLR3 or LMW polyI:C (an TLR3 agonist) but not by pre-treatment with TLR4 antibodies or LPS 
(an TLR4 agonist) (Fig. 2c, Student t-test, p < 0.01). Conversely, pretreatment of DCs with FvmiR168 reduced 
polyI:C binding by almost 50% (Fig. 2d, p < 0.01). Fluorescence microscopy showed that FITC-labeled FvmiR168 
distributes in the citoplasm forming clusters that co-localize with endosomal TLR3 (Fig. 2e).
FvmiR168 interferes with TRIF signaling. We next examined the effect of FvmiR168 on the TRIF 
signaling pathway shared by TLR3 and TLR4. In DCs incubated with FvmiR168 for up to 1 hr no changes in 
the transcript levels of TRIF, IFNB, IRF3 was observed (Fig. 3a). When FvmiR168 pre-treated DCs were sub-
sequently incubated with polyI:C or LPS, a significant reduction of TICAM1 (TRIF,) IRF3 and IFNB mRNA 
was observed after 4 hr as compared with untreated DCs (Fig. 3b,c, Student t-test, p < 0.01). However, with LPS 
(but not polyI:C), the reduction of these transcripts was preceded by a significant but transient increase already 
after 30 minutes of treatment (Fig. 3c, p < 0.05), suggesting the involvement of a negative feedback mechanism. 





















Table 1.  Sequences of the plant-derived miRNAs used. Synthetized both methylated at the 3′-terminus or 
not, according to their plant origin and the experiment performed.
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Figure 1. Effects of plant miRNA treatment in human immune function. (a,b) Effects of miRNA treatment 
on DC activation. DCs were exposed for 2 hr to FvmiR168 (10 ng/ml) and then exposed to LPS or PolyI:C 
(PIC, 10 ng/ml). After 24 hr IL-1β , TNFα , IL-10, IL-6 released on supernatant (a) and costimulatory markers’ 
expression on DC surface (b) have been measured. (c) Effects of treated DCs in stimulating T cells. T cells 
were exposed to DCs, in presence or not of miRNAs (10 ng/ml) and LPS or PolyI:C (10 ng/ml). After five days, 
proliferation has been measured as [3H]-Thy uptake by liquid scintillation [3H]-Thy. Data have been expressed 
as stimulation index: percentage of stimulation above background is determined for each stimulated sample, 
through comparison with results from an unstimulated sample. (d) Superntants have been collected, before 
addition of [3H]-Thy and INFγ release was assayed. In parallel, on the DCs used for the MLR assay IL-12p70 
have been measured on 24 h supernatants. (e) In parallel, on the same set of T cells stimulated with LPS were 
not treated with [3H]-Thy and to characterize the T cell population present in the samples, intracellular staining 
was performed to evaluate the expression of Tbet, Rorγ t and Gata3 by flow cytometry as well as the intracellular 
cytokine production for IL-10, IFNγ and IL-17. Data are presented as mean + SD, N = 5, *p < 0.05, **p < 0.01, 
Student t-test, pretreatment (+ FvmiR168) vs no pretreatment (none, LPS or PIC alone). (f) CCR7 expression 
on DCs surface. DCs were exposed for 2 hr to miRNAs (10 ng/ml) and then exposed to LPS (10 ng/ml) for 24 hr. 
Thereafter, CCR7 expression was evaluated by flow cytometry on CD11c+ gated cells. Data are presented as 
mean + SD, N = 3, *p < 0.05, **p < 0.01, Student t-test, pretreatment (+ FvmiR168) vs no pretreatment (none, 
LPS or PIC alone).
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following 2 hr pre-treatment with Fvmir168 was significantly increased after 20 hr exposure to LPS but not 
PolyI:C (Fig. 3d, p < 0.05).
The immuno-modulatory effect of plant miRNA is not sequence or plant specific. Given that 
dsRNA binding to TLR3 is not sequence-dependent, we tested whether the anti-inflammatory efficacy shown by 
FvmiR168 could also be observed with other miRNAs such as FvmiR156, another abundant strawberry miRNA, 
bolmiR874 an abundant cabbage miRNA or osamiR168 from rice, the plant miRNA detected in blood plasma of 
human and animal subjects after dietary consumption of rice29. DCs treatment with synthetic equivalents of these 
plant miRNAs reduced T cell proliferation to a similar extent than FvmiR168 (Fig. 4a, p < 0.01).
To investigate the possibility that the observed effect may be a general property of plant miRNAs, we obtained 
RNA extracts from a range of plant species and organs including strawberry, blueberry, raspberry and grapevine 
fruits, cabbage, sage, pine and thale-cress leaves, fern fronds, apple peel, cabbage flowers, and wild rice and corn 
caryopses. The sRNA fraction of each extract was separated from the high molecular weight RNA and incu-
bated at a concentration of 10 ng/ml with DCs. All of the tested extracts significantly attenuated the LPS-induced 
T cell proliferation with some extracts (sRNA from cabbage leaves, fern fronds, and apple peel) inducing an 
anti-inflammatory response equal or greater than FvmiR168 alone (Fig. 4b, p < 0.01). On the contrary, sRNA 
extracted from human epithelial (Caco2-derived) cells or beef muscle did not exert any anti-inflammatory effect 
(Fig. 4c). To evaluate the active fraction in the sRNA immuno-modulatory properties, plant-derived total sRNAs 
have been exposed to polyacrylamide gel fractioning as reported in Material and Methods. Among the three 
fractions recovered, the sRNA fraction comprised between 10 and 60 nt, enriched in 21nt sequences, including 
miRNAs (Supplementary Fig. 2), showed a strong anti-inflammatory activity (p < 0.01) whilst, the fractions from 
70 up to 150 nt did not have any significant effect (Fig. 4d). Conversely, the 10–60 nt fraction from total sRNA 
extracted from beef muscle did not exert any anti-proliferative effect on T cells (Fig. 4e).
Figure 2. Plant miRNA interacts with TLR3. (a,b) DCs enter in contact with plant miRNA. DCs were treated 
for 2 hr with 10 ng/ml FITC-labeled FvmiR68. Contact has been evaluated by assessing the number of green 
cells by flow cytometry on specifically gated population (a). Data are presented as mean + SD, N = 3 plus 
representative plots. (b) Representative images of green fluorescent cells after FvmiR168 treatment.  
(c) DCs bind FvmiR168 through TLR3. CD11c-APC–labeled DCs were incubated with FITC-labeled FvmiR168 
in the presence or absence of LPS, LMW poly:IC (PIC), anti–TLR4 mAb, anti-TLR3 mAb, and anti–ALCAM 
Ab as control. Cells were then analyzed for positivity to FITC by flow cytometry. Basal binding (TSA) is set 
as 100%. Data are presented as mean ± SD (N = 4). **p-value < 0.01, Student t-test, blocked vs not-blocked 
cells (none). (d) PolyI:C competes with miRNA for TLR3 binding. CD11c-APC–labeled DCs were incubated 
with FITC-labeled PolyI:C in the presence or absence of FvmiR168. Cells were then washed and analyzed for 
positivity to FITC by flow cytometry. Basal binding (TSA) is set as 100%. Data are presented as mean ± SD 
(N = 7). *p-value < 0.05, **p-value < 0.01, Student t-test, blocked vs not-blocked cells (none). (e) Fluorescence 
microscopy reveals that TLR3 (in red) localizes with FvmiR168 (green) in DCs (nucleus staining in blue, DAPI) 
as indicated by white arrows.
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3′-OH methylation partially accounts for plant miRNA immuno-modulatory property. As plant 
miRNAs are characterized by a 2′ -OH-methylation at their 3′ end39, we next explored whether this structural 
modification may explain their sequence-independent mode of action. Treatment with un-methylated forms 
of FvmiR168 or bolmiR874 significantly reduced LPS-induced T cell proliferation and IFNγ production, albeit 
to a lower extent than treatment with the methylated forms (Fig. 5a). On the other hand, an anti-inflammatory 
Figure 3. Plant miRNA acts on TRIF-mediated signaling. (a) DCs were treated or not for 30’ and 1 hr with 
10 ng/ml FvmiR68. Cells were then collected, RNA extracted and levels of TRIF (TICAM1), IFNB, and IRF3 
were detected by quantitative real-time PCR. (b,c) DCs were treated or not for 1 hr with 10 ng/ml FvmiR68, and 
then exposed for 30’, 1 hr and 4 hr to LPS (b) or PolyI:C (b, PIC). Cells were then collected, RNA extracted and 
levels of TRIF (TICAM1), IFNB, and IRF3 were detected by quantitative real-time PCR. Results are shown as 
means ± SD (N = 3). *p-value < 0.05, **p-value < 0.01, Student t-test treated (+ FvmiR168) vs not-treated cells 
(none, LPS or PIC alone). (d) DCs were treated or not for 2 hr with 10 ng/ml FvmiR68 and then exposed for 
20 hr to LPS (10 ng/ml) or PolyI:C (10 μ g/ml). IDO expression has been analyzed by intracellular straining on 
gated CD11c+ DCs. Results are shown as means ± SD (N = 3). Above the graph a representative flow cytometry 
dot plot has been shown. *p-value < 0.05, Student t-test, pretreatment (+ FvmiR168) vs not-pretreated cells 
(none).
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efficacy, albeit statistically less significant than that exerted by plant miRNAs, could be conferred to miR378 from 
beef muscle (btamiR378) or GFPs duplex by introducing a methylation on the 3′ end (Fig. 5b).
Plant sRNAs reduce the pathology development of EAE in mice. We next explored the efficacy 
of plant sRNA extracts in reducing the inflammatory process in vivo using a mouse model of multiple sclerosis 
(Experimental Autoimmune Encephalomyelitis, EAE)40 induced in C57BL/6 mice by immunization with myelin 
oligodendrocyte glycoprotein peptide 35–55 (MOG35–55 peptide). We tested a “cocktail” containing equal parts of 
the most effective sRNA (extracted from cabbage leaves, fern fronds and apple peel) dissolved in PBS and DOTAP 
(vehicle) to give the final dose of each extract of 10 μ g/ml. sRNA cocktail or vehicle were given by intravenous 
injections at the early stage of the disease from three days post immunization (d.p.i.) and every four days for the 
entire duration of the disease (up to 25 d.p.i.) and the effects on EAE severity examined daily.
No significant difference in body weight was observed between the treated groups and the untreated (control) 
group during the experimental period (data not shown). Mice from all groups developed the disease with the 
typical clinical signs. However, the plant sRNA-treated group displayed significantly attenuated clinical manifes-
tation of EAE when compared to untreated and vehicle-treated mice (Fig. 6a). The mean of disease onset (8 d.p.i.) 
and maximum EAE score (15 d.p.i.) from the plant sRNA group was significantly lower compared to control 
groups (one way Anova, p < 0.05). These results indicated that plant extract administration conferred protection 
against EAE, promoting a less severe disease.
Following EAE induction, both untreated and plant sRNA- or vehicle-treated mice showed distinct areas 
of immune cell infiltration in the spinal cord but the plant sRNA-treated mice had visually less infiltrates than 
untreated or vehicle-treated mice (Fig. 6b). In addition, more numerous and larger plaques of demyelination 
were observed at the site of inflammatory cell infiltrates of untreated and vehicle-treated mice than in plant 
sRNA-treated mice (Fig. 6b). Hystological data correlate with immunohistochemical findings, where we show the 
absence of CD11c infiltrates in spinal cord areas of immune cell invasion (Fig. 6b, IF panel). These results indi-
cate that the less severe disease developed by plant sRNA-treated mice is associated with improved histological 
Figure 4. Effects of different plant sRNA extracts on T cell proliferation. (a–d) T cells were exposed to DCs, 
in presence or not of FvmiR146, bolmiR874 or osamiR168 (10 ng/ml, (a), F. vesca total sRNA (b) or human and 
B. taurus total sRNA (10 ng/ml, (c) or sRNA fractions obtained as described in Material and Methods section 
(10 ng/ml, (d) or B. taurus total and 10–60 nt sRNA fraction (e), and LPS (10 ng/ml). Fractioning of sRNA has 
been performed by polyacrylamide electrophoresis separation. Panel (d) refers to the results obtained using 
10–60 nt sRNA, 70–100 nt sRNA and 100–150 nt sRNA. After five days of T cells-DCs co-cultures, proliferation 
has been measured as [3H]-Thy uptake by liquid scintillation [3H]-Thy. MLR results are shown. Proliferation is 
presented as stimulation index, Percentage Stimulation above background is determined for each stimulated 
sample, through comparison with results from an unstimulated sample. Mean ± SD, N = 6, *p < 0.05, **p < 0.01, 
Kruskal Wallis, pretreatment (+ miRNA duplexes or sRNA fractions) vs not-pretreated cells (none).
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outcomes in the spinal cord, due to difference in infiltrate composition. At the end of the experiment (25 d.p.i) ex 
vivo analyses of DC and T lymphocytes isolated from EAE lymphonodes of the three mice groups and measure-
ments of cytokine production were performed. Analyses of the RNA levels of key transcription factors driving 
T-cell differentiation showed a reduction in the expression of master regulators of pro-inflammatory Tbet and 
Rorc (Student t-test, p < 0.01) genes but, unexpectedly, a significant reduction of the IL-10 master regulator FoxP3 
was also observed (Fig. 6c, p < 0.05). A significant reduction of the inflammatory cytokines IFNγ , IL-17, TNFα , 
CXCL2 and IL-6 in the sRNA-treated group was observed (Fig. 6d, Student t-test, p < 0.05, p < 0.01). Surprisingly, 
this reduction was not associated to an increase in the anti-inflammatory IL-10 production. These results indicate 
that the sRNA effect on the EAE inflammatory phenotype occurs via a FoxP3-independent mechanism.
Although CD11c+ DCs isolated from draining lymphonodes showed similar levels of MHCII, CD80, CD83 
and CD86 expression in all treatments (Supplementary Fig. 3), both in vivo and in vitro suggesting a reduced 
efficiency in T cells polarization toward encephalytogenic Th1 and Th17 production and reduced CNS migratory 
ability.
Discussion
DCs are the master regulators of immune signaling, orchestrating responses to external signals and instructing 
T cells in the type of inflammatory or tolerogenic responses to be exerted, sensing both live microbial cells and 
other microbial antigens, including RNAs41. Over the past decade a substantial amount of scientific literature has 
highlighted the fundamental regulatory role played by miRNAs in the regulation of DC function7,37,42, and devel-
opment, differentiation, and function of T and B cells in autoimmune diseases43. miRNAs can also be naturally 
transferred via exosomes9,27,44 and miRNA-mediated cross-talk between cancer cells and neighboring immune 
cells with ensuing pro-inflammatory changes through direct binding to PRRs was demonstrated26,45. Thus, the 
Figure 5. Effect of plant miRNA 3′OH-methylation on T cell proliferation. (a) T cells were exposed to DCs, 
in presence or not of 10 ng/ml methylated FvmiR168, bolmiR874 or their un-methylated analogs. After five days 
of T cells-DCs co-cultures, proliferation has been measured as [3H]-Thy uptake by liquid scintillation. MLR 
results are shown. Proliferation is presented as stimulation index, Percentage Stimulation above background 
is determined for each stimulated sample, through comparison with results from an unstimulated sample. In 
parallel, IFNγ was assayed on 5-days supernatants collected before [3H]-Thy addition. (b) Similarly, T cells 
were exposed to DCs, in presence or not of 10 ng/ml btamiR378 or the GFPs duplex and their methylated 
analog. MLR results and IFNγ production are shown. Mean ± SD, N = 4, *p < 0.05, **p < 0.01, Kruskal Wallis, 
pretreatment (+ miRNA duplexes or sRNA fractions) vs not-pretreated cells (none). $p < 0.05, $$p < 0.01, 
Student t-test, methylated vs un-methylated miRNA pretreatment. um, un-methylated; meth, methylated.
www.nature.com/scientificreports/
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Figure 6. Effect of plant sRNA in EAE. (a) sRNA significantly ameliorated the clinical signs and disease 
progression of EAE. Analysis was performed by one way Anova test indicating that curves are statistically 
different (*p < 0.05). In particular clinical score is statistically significant in pool sRNA vs untreated mice and 
in pool sRNA vs vehicle treated mice at 8 and 15 days after immunization (d.p.i). (b) Effect of treatment with 
plant extract on inflammation and demyelination in the spinal cord of EAE mice. Sections were stained for 
Haematoxylin and Eosin (H&E) and LFB and examined to detect inflammatory infiltrates and demyelination, 
respectively, as indicated by arrows. Staining displayed a decrease of the number of infiltrates (arrows) in the 
white matter in the spinal cord of plant sRNA-treated mice compared to untreated or vehicle treated mice. Luxol 
Fast Blue (LFB) staining indicated a similar pattern after pool-sRNA treatment (arrows). Immunofluorescence 
analysis (IF) has also been performed. Section were stained with CD11c+ (RED) and Iba1 (green) to detect 
DCs and microglia respectively, and counterstained with DAPI (blue). Magnification of the black frames in 
upper panels are shown. CD11c infiltrates are absence in the spinal cord areas of immune cell invasion of plant 
sRNA treated mice. (c,d) Ex vivo analysis of T lymphocyte isolated from EAE lymphnodes. T cells were treated 
with ex vivo with MOG. To characterize the T cell population present in the samples, intracellular staining was 
performed to evaluate the expression of Tbet, Rorc, Gata3, Foxp3 and cMaf. Mean ± SD of two independent 
experiments (c). On cytokine supernatans, IL-10, IL-17, IFNγ , TNFα , IL-6, CXCL1 and CXCL2 were measured 
(d). *p < 0.05, **p < 0.01, Student t-test, treatment vs no treatment.
www.nature.com/scientificreports/
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recent evidence presented in support of plant miRNA uptake through the diet in human and animals, poses 
intriguing questions concerning the role of the immune system in diet-health interactions. We report here that 
exposure of DCs to synthetic strawberry fruits FvmiR168, packaged in exosome-like structures, does not modify 
their ability to induce T cell proliferation and differentiation. However, subsequent exposure of FvmiR168-treated 
DCs to LPS or polyI:C, agonists of TLR4 and TLR3 respectively, results in a strong reduction in the inflammatory 
response and this effect appeared associated to a decreased expression of TRIF transcript, downstream trans-
ducer of TLR3 and TLR446. FvmiR168 appears to interact directly with TLR3 as demonstrated by its intracellular 
co-localization with endosomal TLR3 and decreased binding in the presence of TLR3 antibody. This finding is 
not surprising since TLR3 is the transmembrane PRR deputed to detection of dsRNA23. Although dsRNA ligands 
must be at least 45–49 nt in length to bind to TLR3 ectodomains and induce its functionalization through cooper-
ative dimerization47,48, activation of TLR3 signaling has also been observed with shorter (from 20 to 40 nt) dsRNA 
ligands such as siRNAs49,50.
However, here we show that binding of FvmiR168 (21 nt in length) to TLR3 in DCs not only does not activate 
their pro-inflammatory response but it strongly represses their signaling in the presence of polyI:C and, surpris-
ingly, LPS. Our results are consistent with the effects induced by dsRNA species below 20 nt in length which were 
shown to bind to the ectodomain of TLR351 but failed to induce stable homodimer complexes52 and ensuing acti-
vation of the downstream signaling47,49. One possibility is that FvmiR168 pre-treatment of DCs promotes unpro-
ductive sequestration of TRIF adaptor to the TLR3 TIR domain, resulting in down-regulation of TRIF signaling 
following DCs exposure not only to polyI:C but also LPS, a TLR4 agonist. Intriguingly, the dynamics of TRIF 
signaling transcripts following LPS treatment indicate the induction of a feedback loop involving IDO expression 
which is known to be TRIF dependent53 and IDO-competent DCs are capable of inhibiting T cell proliferation in 
vitro54 and might induce tolerance in vivo55.
Although a direct impact of FvmiR168 on TRIF mRNA cannot be excluded, the finding that 
anti-inflammatory efficacy of FvmiR168 could be replicated by other plant miRNAs sequences (FvmiR156, bol-
miR874, osamiR168) and even miRNA-rich sRNA extracts from a wide range of plants, suggests the involvement 
of a sequence-independent mechanism, such as interaction with PRRs. Indeed, this property appears to be a 
sequence-independent “class-attribute” of plant miRNAs as it was also observed with the fraction of 10–60 nt in 
length of sRNA extracts obtained from a wide range of plant species but not from mammalian sources (human 
Caco2 cell line or Bos taurus muscle). As nucleosides methylation of dsRNA interferes with their ability to ini-
tiate sequence-independent pro-inflammatory response56 and 2′ -O-methylation at the 3′ end is a class attrib-
ute of plant miRNAs and siRNAs39, we reasoned that such structural modification may be responsible for the 
specific properties of plant sRNA extracts. However, removal of the 3′ end methylation from plant miRNAs 
sequences (duplexes) reduces but does not abolish their anti-inflammatory potency. Moreover, the introduc-
tion of a 2′ -O-methylation at the 3′ end of mammalian or GFP miRNA duplexes, although effective in con-
ferring some anti-inflammatory efficacy, it does not replicate that of methylated plant miRNAs. These results 
suggest that a 3′ end methylation of miRNAs duplexes is an important but not sufficient requisite to explain their 
anti-inflammatory efficacy in our experimental system. It is feasible that 3′ end methylation of miRNA could 
promote their stability and/or directly mediate their interaction with TLR3. However, other structural properties 
are required to promote a full anti-inflammatory effect and these seem to be found specifically in natural plant 
miRNAs. Further work is required to unveil the exact mechanism underpinning the secondary plant miRNA 
structure responsible for their immuno-modulatory effects.
The therapeutic potential of plant miRNAs was confirmed in a mouse model of human multiple sclerosis, 
EAE induced by active MOG immunization, where intravenous injections of 1.5 μ g of DOTAP-complexed plant 
sRNA extracts significantly attenuate the pathology development of EAE. Clinical amelioration was associated 
with decreased spinal cord inflammatory infiltrates, that vary also in cell composition, and consequent decreased 
demyelination. Treated animals showed different T cell subpopulation profiles with diminished IFNγ and IL-17 
production, indicative of diminished lymphocytes polarization toward Th1 and Th17, master effectors of EAE. 
This shift was confirmed by the quantitative evaluation of T cell transcription factors that characterize the T 
cell phenotype. Although the sRNA treatment down-modulated FoxP3 expression, a transcription factor that 
normally identifies Treg, the expected reduction of IL-10 production was not observed. We know that FoxP3 
may vary with cell activation57 increasing the relative expression in early-activated cells without affecting Treg 
differentiation. The reduced FoxP3 expression we observed in our sample is an indication of reduction in T cell 
activation following plant sRNA treatment. As our in vitro data suggest that this is not the result of a direct effect 
of plant miRNA on T cells, we may explain the in vivo results as DCs mediated action on immunogenic, MOG 
specific T cells. CD11c+ DCs from draining lymphonodes were apparently matured. Yet the plant sRNA-treated 
mice lymphonode isolated DCs may be less efficient in T cells polarization toward encephalytogenic Th1 and 
Th17 production, because of the reduced production of soluble factors, i.e. IL-12, IL-6 and TNFα . Furthermore, 
the reduced expression of CCR7 observed in vitro leads to impaired migratory ability of DCs in the presence of 
FvmiR168, and may explain the reduced efficiency of T cell priming and activation in lymphonodes and CNS 
observed in vivo. Altogether these results suggest that the plant sRNA effect on the EAE occurs via reduction 
of primary inflammatory signaling mediated by DCs, and consequently reduced priming of Th1 and Th17 cells 
formation at the immune synapse. This mechanism does not require FoxP3-mediated Treg differentiation and 
secondary suppression of inflammation. This evidence is in agreement with previous observations that TLR3 
defective mice show reduced CNV inflammation58, indicating that interfering with Trif-TLR3 mediated inflam-
mation is a viable approach for treatment of autoimmune disorders.
Thus we show here that the anti-inflammatory properties of plant miRNAs and sRNAs may have both pre-
ventive and therapeutic efficacies. By shaping the regulation of inflammation, dietary plant miRNAs could early 
on moderate responses to inflammatory stimuli later in life, thus reducing chronic diseases59. We conclude that 
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better understanding of the cross talk between exogenous miRNA and immune function will open novel oppor-
tunities to the development of an entirely new class of miRNA based anti-inflammatory drugs.
Methods
Ethics statement. The study was designed in conformity with the international recommendation (Dir. EU 
2001/20/EC) and its Italian counterpart (DM 15 Luglio 1997; D.Lvo 211/2003; D.L.vo 200/2007) for clinical trial 
and following the Declaration of Helsinki, to assure protection and care of subjects involved. Human peripheral 
blood mononuclear cells (PBMCs) were isolated from buffy coats provided by Careggi Hospital (Florence, ethical 
approval document n. 87/10), or by Centro Trasfusionale of Santa Chiara Hospital (Trento, ethical approval docu-
ment n. 54896583) after obtaining ethical approval by their respective internal ethical committees, as indicated in 
brackets. Written informed consent has been obtained from all the adult subjects. All animal manipulations were 
performed in the animal facility at the CeSaL (University of Florence) according to the European Community 
guidelines for animal care (DL 116/92, application of the European Communities Council Directive 86/609/EEC) 
and the Guiding Principles for Research Involving Animals Beings. Experimental procedures were approved by 
the Committee for Animal Care and Experimental Use of the University of Florence.
Synthetic miRNA. Synthetic miRNA duplexes (Table 1) were synthesized by Sigma Genosys and purified by 
HPLC with the addition of the specific methyl modification at the 3′ termini. The annealing of small RNA strands 
was performed as described by Sigma oligo synthesis service. Upon arrival the small RNA duplexes were resus-
pended in RNAse-free water to the appropriate concentration. In each experiment miRNAs were complexed with 
DOTAP Liposomal Transfection Reagent (Roche) which facilitates nucleic acid entry into the cells36,60. In each 
experiment, DOTAP is also added to the control cells to exclude cross reactivity.
Cell preparation. The PBMC fraction was obtained by density centrifugation of diluted blood over 
Ficoll-Paque (GE Healthcare). Monocytes were isolated from low density PBMCs by magnetic enrichment 
with anti-CD14 MicroBreads (Miltenyi Biotec) and cultured as previously described to allow DC differentia-
tion61. DC activation was induced by LPS (10 ng/ml, Sigma Aldrich) or Low Molecular Weight (LMW) PolyI:C 
(10 μ g/ml, InvivoGen). Total CD4+ T cells were obtained from PBMC by negative isolation with a combination of 
magnetic sorting (CD4+ T Cell Isolation II Kit). Depending on the experiment, supernatants were collected after 
24 hr or 5 d, and stored at 20 °C until the assays. Cells viability was assessed before each experiment by Trypan 
blue (Euroclone) exclusion. DC viability was also evaluated after each experiment by flow cytometry using the 
Annexin V-FITC kit (BD Pharmingen) (Supplementary Fig. 4). The viability was always higher than 95% in all 
the experiments performed.
Mixed lymphocyte reaction (MLR). 1 × 105 CD4+ T cells were incubated, in 96-well U bottom plates, 
for 5 d in RPMI with 10% FBS together with allogeneic DCs, in presence or not of miRNA (10 ng/ml) and 
LPS or PolyI:C. At day 5, the proliferative response was measured by the [3H]-thymidine ([3H]-Thy, 1 μ Ci/mL, 
Amersham Bioscience) incorporation test. [3H]-Thy was added for the last 8 hr of incubation. Plates were har-
vested (Tomtec Mach III, Wallac) on glass fiber filters (PerkinElmer), and [3H]-Thy uptake was measured by 
liquid scintillation in a Microbeta 1450 Trimux counter (Wallac). The proliferative response is reported as a stim-
ulation index (SI, mean cpm response/mean cpm background).
Human cytokine assay. At the indicated times, supernatants from human cell cultures were collected and 
cytokine detection was performed using the Milliplex® MAP human cytokine/chemokine kit (Merck-Millipore), 
according to the manufacturer’s instructions. IL-6, TNFα , IL-1β , IL-10, IL-12p70 and IFNγ were assayed.
Human flow cytometry. For DC surface markers evaluation, cells were labeled with adequate concentra-
tions of labeled antibodies in PBS with 1% FBS for 20 min at 4 °C, washed twice, and analyzed immediately. T cell 
intracellular staining for Tbet, Rorγ t, IL-17A, IL-10 and IFNγ were performed using the fixation/permeabiliza-
tion buffer kit (Life Technologies) following the manufacturing recommendations. A minimum of 10000 events 
for each sample were acquired using a Guava easyCyte 8T flow cytometer (inCyte software,Merck-Millipore). 
The area of positivity was determined by using an isotype-matched control MAb. Antibodies used: Fluorescein 
isothiocyanate (FITC)–anti-IL17A, phycoerythrin (PE)–IL10, APC–anti-CD4, APC-anti-CD11c, PE-IL-10, 
FITC-Tbet (Merck-Millipore), PE-Cy7 Tbet, APC-Rorγ t, PE-IFNγ , PE-CD11c, (BD Biosciences Pharmingen); 
FITC-CCR7 (eBioscience); FITC-CD80, PE-CD86, ECD-HLADR and PC5-CD83 (Beckman Coulter).
Binding assay. FvmiR168 was labeled with fluorescein using the 5′ End-Tag kit (Vendor Laboratories) follow-
ing the manufacturer’s instruction. The labeled miRNA was then added at a concentration of 10 ng/ml to DCs. After 
2 hr, cells were visualized for green-positivity by flow cytometry. In parallel, cells were visualized at fluorescence 
microscope. To test the effects of various reagents on ligand binding, the following concentrations were used: LPS 
(1 μ g/ml), LMW poly:IC (10 μ g/ml), anti–TLR4 mAb, anti-TLR3 mAb (both from InvivoGen) and anti–ALCAM 
Ab (30 μ g/ml). Incubation was performed in 20 mM Tris, pH 8.0, 150 mM NaCl, 1 mM CaCl2, 2 mM MgCl2, and 1% 
BSA. After 1 hr of incubation at 37 °C, cell–miRNA conjugates were analyzed by flow cytometry. DCs were labeled 
with anti-CD11c-APC to discriminate cells binding FITC-labeled miRNA from free miRNA-containing vesicles.
Quantitative real time PCR. Total RNA was extracted with the RNeasy Mini Kit (Qiagen, Valencia, CA). 
SuperScript® VILO cDNA Synthesis Kit (ThermoFisher Scientific) was used for cDNA synthesis. Transcripts for 
TRIF/TICAM, IRF3 and IFNB1 were quantified with Applied Biosystems predesigned TaqMan Gene Expression 
Assays and reagents according to the manufacturer’s instructions. Quantification of the PCR signals was 
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performed by comparing the cycle threshold value of the gene of interest with the cycle threshold value of the 
reference gene GAPDH. Values are expressed as fold increase of mRNA relative to that in not treated cells.
smallRNA preparation. Plant, epithelial (Caco2-derived) and beef derived-sRNAs were extracted with the 
cetyltrimethylammonium bromide (CTAB)-based method62 or using the mirPremier microRNA Isolation Kit 
(Sigma-Aldrich) according to the manufacturer’s protocol. The use of CTAB together with Polyvinylpyrrolidone 
(PVP 40) followed by three successive chlorophorm:isoamyl alcohol extractions - or, as in the case of the kit, the 
use of filtration columns - allowed to denature and eliminate the protein complex present in the sample. After 
each extraction, samples will be analyzed using the Agilent RNA 6000 Nano Kit through the BioAnalyzer instru-
ment (Agilent Technologies), for checking purity from high molecular weight RNA. Furthermore each sRNA 
preparation were analyzed using the Agilent Small RNA kit, to characterized the size of the sRNA present in each 
fraction. Size determination has been assessed on the basis of the retention time with respect to the known sizes 
and timing of the ladder peaks. The sRNA content ranged between 10 and 150 nt for all the plant used.
Gel fractioning of sRNA. A standard 12% acrylamide gel [1X TBE, 12% acrylamide (19:1 acryl:bis-acryl)] 
was used to separate the plant sRNA. The gel was warmed to ~50 °C by running it for 10–15 minutes at 40 V in 
1X TBE running buffer. 1 μ g of sRNA was combined with an equal volume of Gel Loading Buffer II and then 
used for loading the gel. The gel was run until the leading dye travels about 4–5 cm down the gel, at 70 V. Gel was 
stained with SYBR Gold (Life Technologies) according to manufacturer’s extraction. Different gel slices (covering 
the range from 10 to 60 nt, 70–100 nt and 100–150 nt), were recovered according to the band profile and the two 
ladders used (the Low Range ssRNA Ladder and the microRNA Marker, both from New England BioLabs inc.) 
and crushed in 1 M NaCl and incubated overnight at 4 °C. The day after, the samples were centrifuged for 5 min at 
2000 g and the supernatant transferred to a 50 ml tube. Crushed gel slices were re-elute with 2 ml of 1 M NaCl for 
1 hr at room temperature and centrifuged again. The pooled supernatants were purified with MEGAclear Kit (Life 
Technologies). Obtained fractions were analyzed using the Agilent Small RNA kit, to check the sizing and purity 
of the fractionation performed as well as the miRNA (21 nucleotides) content, according to the manufacturer’s 
software.
Induction and clinical assessment of EAE. Six to eight-week old C57Bl/6 female mice were obtained 
from Harlan, Italy Srl. The mice were housed in macrocolon cages on a 12 hr light/dark cycle at 23 °C, with ad 
libitum access to food and water. Adequate measures were taken to minimize pain and discomfort. Mice were 
immunized subcutaneously in the flanks and at the base of the tail with a total of 200 μ g of MOG35–55 (synthesized 
by EspiKem Srl, Università di Firenze) per animal emulsified in complete Freund adjuvant (Sigma-Aldrich) sup-
plemented with 4 mg/ml of Mycobacteriun tibercolosis (strain H37Ra; Difco Laboratories). Immediately there-
after, and 48 hr later, the mice received an intraperitoneal injection of 500 ng pertussis toxin (Sigma-Aldrich) in 
100 μ l of phosphate buffer saline (PBS). The animal were examined daily for weight loss and disability, and were 
clinically graded by investigators blind to group identity, as follows: zero indicate no signs, 0.5 partial loss of tail 
tonicity, 1 paralyzed tail, 2 ataxia and difficulty in righting, 3 paralysis of the hind limbs and/or paresis of the 
forelimbs, 4 tetraparalysis, 5 moribund or death.
Treatments. Plant sRNA (pool of three plants, total of 30 μ g/mice), obtained as described above was freshly 
dissolved in PBS/DOTAP (60 μ l/mice, stock solution 1 μ g/μ l before injection heated 20′ at 37 °C. 150 μ l of PBS/
DOTAP/plant extract or vehicle were intravenously injected every four days from 3 d.p.i. to 22 d.p.i. for a total of 
six injections. At 25 d.p.i. animals were sacrificed.
Neuropathological evaluations. At the time of sacrifice, the mice were anesthetized with pentobarbital (65 mg/kg, 
intraperitoneally). The spinal cord was removed from the column and fixed in 4% (v/v9 paraformaldehyde in 
PBS) and subsequently paraffin-embedded. Five micrometers thick transversal sections were cut and placed 
on glass slides. Serial sections were stained with Haematoxylin and Eosin (H&E), Luxol Fast Blue (LFB)-cresyl 
violet. Immunohistochemistry analysis was performed as reported57 with anti-Iba1 (rabbit anti-mouse, Wako 
Chemicals) and anti-CD11c (hamster anti-mouse , eBioscience) as primary antibodies and anti-rabbit AlexaFluor 
488 and anti-hamster AlexaFluor 546 (eBioscience) as secondary antibodies.
Immunological evaluations. Cells were isolated from draining lymphonodes of EAE animals and analyzed for 
T cell proliferative response, dendritic cell phenotype, T cell cytokines production and expression of transcrip-
tion factors. Briefly, DCs phenotypes were investigated for surface marker expression by mean of flow cytome-
try: after staining with fluorescent monoclonal antibodies directed against MHC II, CD11c, CD80, CD86 and 
CD83 (all eBioscience), cells were analyzed on a four-color Epics XL cytometer (Expo32 software; Beckman 
Coulter). T lymphocytes of MOG35–55 immunized mice treated or not were cultured in complete RPMI in 96 
well plates (200000 cells/well) and stimulated with antigen. At day 3, the proliferative response was measured 
by 3H-thymidine incorporation test. Cytokines (IFNγ , IL1-7, TNFα , CXCL1, IL-6, CXCL2 and IL-10) were 
determined by Luminex (Kit Milliplex, Merck-Millipore) in cell supernatants harvested after 4 days of antigen 
stimulation (1 million cells/ml/well). Total RNA was extracted from lymphonodes’ cells isolated at sacrifice by 
using Qiazol following manufacturer’s protocol (Qiagen). cDNA was synthesized with RT quantitect (Qiagen). 
Real-time PCR was performed with an ABI Prism 7900HT Sequence Detection System (Applied Biosystems), 
according to manufacturer’s instructions. All PCR amplifications were performed with TaqMan Universal Master 
Mix and with Assay-on-demand (Applied Biosystems). Relative expression of mRNA levels was determined by 
comparing experimental levels with a standard curve generated with serial dilution of cDNA obtained from 
human PBMCs. Ubiquitin carboxy-terminal hydrolase L1 (Hprt1 Hypoxanthine phosphoribosyltransferase 1) 
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was used as a housekeeping gene for normalization. In each sample the level of the following mRNA level were 
evaluated: Gata3, Tbet, Foxp3, cMaf and Rorc. Ratio of transcription factors were calculated within each animal 
and means were compared.
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